Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a preclinical stage pharmaceutical company with a groundbreaking focus on telomere regeneration and age-related inflammatory diseases. Its lead drug candidate, Telomir-1, presents a novel approach to extending telomeres, potentially reversing aging processes and addressing age related conditions such as osteoarthritis.